Lunai Bioworks announces regression of tumors with immune cell therapy

Lunai Bioworks (LNAI) has announced a major scientific breakthrough: its next-generation immune cell therapy led to complete regression of both primary and metastatic pancreatic tumors in humanized mouse models. Images of control and 2nd Gen treatment condition mice using in vivo imaging system. Live imaging system was utilized to capture the tumor growth at various timepoints. The DC treated mouse showed absent signals of tumor at 5-week post dosing. The study was published in a new Brief Report in Vaccines on November 2, 2025. The peer-reviewed Brief Report details the development of a second-generation, clinical-grade DC construct that achieved complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models. Pancreatic cancer is one of the deadliest cancers, often diagnosed late and resistant to conventional treatments. Lunai’s therapy uses engineered dendritic cells – specialized immune cells created from stem cells – that are genetically enhanced to activate the body’s immune system against cancer. This publication details a second-generation, clinical-compliant version of this platform, with the provided evidence critical in advancing ongoing partnering conversations for the therapy.